October 2025 FDA Recall Drug by Teva Pharmaceuticals Usa, Inc
D-0151-2026 - Subpotent drug; Clavulanate Potassium component

This Class II drug recall was voluntarily initiated by Teva Pharmaceuticals Usa, Inc on October 13, 2025 for the product Drug. The FDA reported the reason for recall as subpotent drug; clavulanate potassium component. The product was distributed in Distributed in three (3) States: MS, OH, CA. and the recall is currently ongoing.

Recall Number: D-0151-2026

Reason for Recall
Subpotent drug; Clavulanate Potassium component
Initiated
10-13-2025
Reported
11-12-2025
Quantity
4680 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Teva Pharmaceuticals USA, Inc
Distributed in three (3) States: MS, OH, CA.
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.

Batch or Lot Expiration Information

Lot# 100062316, Exp Date: 01/2026